Wallar Gina M
Known title: President, Pharma ServicesCIK: 0001869819
Associated companies
Transaction History
| NEO | ▲ Buy | Grant | 11,677 | $0 | 3/1/2022 | View on chart |
| NEO | ▲ Buy | Grant | 15,286 | $0 | 12/30/2021 | View on chart |
| NEO | ▲ Buy | Grant | 11,677 | $0 | 3/1/2022 | View on chart |
| NEO | ▲ Buy | Grant | 15,286 | $0 | 12/30/2021 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News
NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.